Skip to content
clinical trials latin america
  • About Cohortias
    • Commitment
    • Our Story
    • Team
    • Why Latin America
  • Careers
  • Cohortias – Clinical Research in Latin America
  • Cohortias – Investigación Clínica en América Latina
    • Contacto
    • Nosotros
      • Compromiso
      • Equipo de Investigación Clínica
      • Historia
      • Investigación Clínica en América Latina
    • Recursos de Investigación Clínica
      • Noticias de Estudios Clínicos: Actualizaciones de COVID-19 (Coronavirus)
      • Rigor Científico en Investigación Clínica
    • Servicios de Investigación Clínica
      • Dispositivos Médicos
      • Ensayos Clínicos de Primeras Fases
      • Estudios Clínicos Fase II y III
      • Estudios de Rescate
  • Contact
  • Insights
    • Clinical Research News
    • Events
    • Our Science
  • Join Us
    • Registration
    • Registration
  • Member Login
    • Password Reset
    • Password Reset
    • Profile
    • Profile
  • Members
  • Privacy
  • Privacy Policy
  • Services
    • Early Phase Trials
    • Medical Devices
    • Phase II & III Trials
    • Rescue Studies
  • Sites and Network
  • Trials
    • Argentina
      • Alecardio Argentina
      • Other Studies – Argentina
      • Spire I & II Argentina
    • Brazil
      • Alecardio Brazil
      • Other Studies – Brazil
      • Spire I & II Brazil
    • Colombia
      • Alecardio Colombia
      • Spire I & II Colombia
    • Mexico
      • Alecardio Mexico
      • Spire I & II Mexico
  • Cohortias Blog

    1. Home>
    2. Cohortias Blog
    Read more about the article Cohortias – New regulation make Argentina an excellent choice for clinical research.
    argentina

    Cohortias – New regulation make Argentina an excellent choice for clinical research.

    • Post author:quickappsmkt
    • Post published:May 19, 2022
    • Post category:Cohortias Blog
    • Post comments:0 Comments

    The new regulation will accelerate the evaluation process from 160 business days to 70 days or less.

    Continue ReadingCohortias – New regulation make Argentina an excellent choice for clinical research.
    Read more about the article Cohortias – The BIO International Convention 2022.
    Bio international

    Cohortias – The BIO International Convention 2022.

    • Post author:quickappsmkt
    • Post published:May 17, 2022
    • Post category:Cohortias Blog
    • Post comments:0 Comments

    For the first time in three years, the BIO International Convention will be back fully in person in San Diego, California.

    Continue ReadingCohortias – The BIO International Convention 2022.
    Read more about the article Clinical Trial – Phase 1 of oral type 2 diabetes new therapy.
    type 2

    Clinical Trial – Phase 1 of oral type 2 diabetes new therapy.

    • Post author:quickappsmkt
    • Post published:May 16, 2022
    • Post category:Cohortias Blog
    • Post comments:0 Comments

    In the trial, GLY-200 was found to be well-tolerated across all tested dose levels without any safety signals detected.

    Continue ReadingClinical Trial – Phase 1 of oral type 2 diabetes new therapy.
    Read more about the article First-in-Human – Phase 1/2 refractory PTCL therapy.
    PTCL

    First-in-Human – Phase 1/2 refractory PTCL therapy.

    • Post author:Nereo.Cohortias
    • Post published:May 12, 2022
    • Post category:Cohortias Blog
    • Post comments:0 Comments

    A Phase II trial will begin to support registration, once Myeloid establishes the recommended dose.

    Continue ReadingFirst-in-Human – Phase 1/2 refractory PTCL therapy.
    Read more about the article Clinical Trial – Phase 2 new covid-19 booster trial.
    booster

    Clinical Trial – Phase 2 new covid-19 booster trial.

    • Post author:quickappsmkt
    • Post published:May 9, 2022
    • Post category:Cohortias Blog
    • Post comments:0 Comments

    In the trial, vaccination with ABNCoV2 led to a substantial improvement in neutralizing antibodies against the Omicron variant.

    Continue ReadingClinical Trial – Phase 2 new covid-19 booster trial.
    Read more about the article First-in-Human – Phase 3 knee osteoarthritis trial.
    osteoarthritis

    First-in-Human – Phase 3 knee osteoarthritis trial.

    • Post author:quickappsmkt
    • Post published:May 6, 2022
    • Post category:Cohortias Blog
    • Post comments:0 Comments

    The trial will evaluate the change in pain and function following subcutaneous injections of PPS versus placebo.

    Continue ReadingFirst-in-Human – Phase 3 knee osteoarthritis trial.
    Read more about the article Clinical Trial – Phase 2 hepatocellular carcinoma therapy.
    hepatocellular

    Clinical Trial – Phase 2 hepatocellular carcinoma therapy.

    • Post author:quickappsmkt
    • Post published:May 5, 2022
    • Post category:Cohortias Blog
    • Post comments:0 Comments

    The open-label trial will assess the safety and efficacy of GT90001 plus Nivolumab in patients with advanced HCC.

    Continue ReadingClinical Trial – Phase 2 hepatocellular carcinoma therapy.
    Read more about the article Clinical Trial – Treatment for glioblastoma multiforme.
    glioblastoma multiforme

    Clinical Trial – Treatment for glioblastoma multiforme.

    • Post author:quickappsmkt
    • Post published:May 3, 2022
    • Post category:Cohortias Blog
    • Post comments:0 Comments

    Assessing the overall survival is the primary endpoint of the global trial.

    Continue ReadingClinical Trial – Treatment for glioblastoma multiforme.
    Read more about the article First-in-Human – Phase 1 osteoporosis drug trial.
    osteoporosis

    First-in-Human – Phase 1 osteoporosis drug trial.

    • Post author:quickappsmkt
    • Post published:April 29, 2022
    • Post category:Cohortias Blog
    • Post comments:0 Comments

    The trial will assess the safety, tolerability, and pharmacokinetics of TST002 to treat individuals with osteoporosis.

    Continue ReadingFirst-in-Human – Phase 1 osteoporosis drug trial.
    Read more about the article Clinical Trial – Phase 3 idiopathic hypersomnia treatment.
    hypersomnia

    Clinical Trial – Phase 3 idiopathic hypersomnia treatment.

    • Post author:quickappsmkt
    • Post published:April 28, 2022
    • Post category:Cohortias Blog
    • Post comments:0 Comments

    The randomized, double-blind trial of Wakix will enroll nearly 200 IH patients in 60 to 80 trial sites in the US.

    Continue ReadingClinical Trial – Phase 3 idiopathic hypersomnia treatment.
    • 1
    • 2
    • 3
    • 4
    • …
    • 35
    • Go to the next page